## FBXL7
- **UniProt:** Q9UJT9 · **batch:** proteostasis-batch-2026-06-13 · **review status:** COMPLETE
- **PN placement:** `UPS|E3 ubiquitin and UBL ligases|Cul1 substrate receptor|F-box|LRR` ; **PN-node mapping:** group-level `mapped / ok_for_propagation_to_go / GO:1990756`; class `context_only / too_broad / GO:0061630`.
- **Consistency:** Strong. Deep research, review, PN annotation, and node mapping all describe FBXL7 as the SCF(FBXL7) receptor degrading AURKA and survivin/BIRC5 (validated: PMID:25778398 IDA, 28218735 IMP; FBXL18→FBXL7 axis PMID:25654763). Falcon extra substrates (c-SRC, SNAI1, PFKFB4) marked UNVERIFIED and held as leads. No contradictions.
- **PN story / NEW pressure:** PN asserts the generic adaptor MF. FBXL7 GOA has NO MF beyond `protein binding` (no catalytic transferase). The review adds `GO:1990756` as **action: NEW (IDA, PMID:25778398)** — exactly the batch-correct call, and it matches the PN-projected term (GO:1990756, goa_status=new_to_goa). Validated substrates already drive `G2/M transition`, `regulation of apoptotic process`, `SCF-dependent catabolism` BPs. Conclusion: adaptor MF correctly ADDED as NEW; no over-reach.
- **Mapping strategy:** Gene does not change the node. Status/scope right; PN-projected GO:1990756 is identical to the review MF (not broader/narrower). Canonical, multiply-validated substrate receptor (AURKA, survivin) — no orphan flag. Note: FBXL7 review already encodes the MF directly, so the PN "new_to_goa" projection is consistent with the review having materialized it.
- **Evidence alignment:** PN cites only "15340381/rev"; review uses gene-specific primaries (25778398, 28218735, 25654763, 33234069) — no overlap with the PN placeholder, richer evidence in review. Benign divergence.
- **Verdict:** CONSISTENT / ACCEPT mapping. Exemplary application of the NEW→GO:1990756 pattern. No edits required.